corticosteroids - versus potential COVID-19 treatments - for COVID-19   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.81 [0.65, 0.99]< 159%7 studies (7/-)97.9 %highnot evaluable lowcrucial-
clinical improvement 1.16 [0.84, 1.60]> 10%2 studies (2/-)81.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.16 [0.84, 1.60]> 10%2 studies (2/-)81.0 %some concernnot evaluable moderateimportant-
clinical worsening 0.66 [0.43, 1.02]< 10%1 study (1/-)96.9 %some concernnot evaluable moderateimportant-
death or ventilation 0.71 [0.37, 1.35]< 10%1 study (1/-)85.3 %lownot evaluable highimportant-
hospital discharge 1.10 [1.03, 1.17]> 10%1 study (1/-)99.8 %some concernnot evaluable moderateimportant-
ventilation 0.95 [0.44, 2.04]< 10%1 study (1/-)55.3 %lownot evaluable highimportant-

-- safety endpoints 00

serious adverse events 1.35 [0.34, 5.30]< 144%3 studies (3/-)33.4 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 2 pathologies: 87,95,94,90,91,97 91, 95